Vol 6, No 4 (2021)
Letter to the Editor
Published online: 2021-11-02
COVID-19 vaccine — third dose, booster dose? What is it and is it necessary?
1, 234
, 5, 2, 2, 3, 6, 2
, 5, 2, 2, 3, 6, 2
Disaster Emerg Med J 2021;6(4):208-209.
Abstract
Not available
Keywords: SARS-CoV-2COVID-19vaccineepidemiologyoutcome
References
- Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021; 325(21): 2204–2206.
- Tenforde MW, Patel MM, Ginde AA, et al. Influenza and Other Viruses in the Acutely Ill (IVY) Network. Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States. Clin Infect Dis. 2021 [Epub ahead of print].
- Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect. 2021 [Epub ahead of print].
- Chodick G, Tene L, Rotem RS, et al. The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data. Clin Infect Dis. 2021 [Epub ahead of print].
- Khan N, Mahmud N. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications. Gastroenterology. 2021; 161(3): 827–836.
- Chemaitelly H, AlMukdad S, Joy J, et al. SARS-CoV-2 vaccine effectiveness in immunosuppressed kidney transplant recipients. .
- Ferenci T, Sarkadi B. Virus neutralizing antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine. .
- Tartof S, Slezak J, Fischer H, et al. Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study. SSRN Electronic Journal. .